The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...

From 2015 and 2021, almost 30% of deaths among residents and fellows were due to suicide. In other news: Medicare fraud at UnitedHealth; patient fall rates at rehab facilities; and more.

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...